Skip To Main Content
Denise Mann on Muck Rack

Denise Mann

Verified
  • Writer and Editor, Freelance
  • Senior Content Director, Advances in Cosmetic and Medical Dermatology
  • None, Dermatology Digest, The
New York
As seen in: CNN, MSN, MSN Australia, MSN Canada, MSN India, MSN Singapore, MSN UK, Yahoo Life, Business Insider, MSN Philippines and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Denise

Contact Denise, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

TDD Launch Pad: What’s New From SkinCeuticals, Panoxyl, and One A Day

|
By Denise Mann Verified
| The Dermatology Digest
In this column, The Dermatology Digest (TDD) highlights some of the newest launches in the skincare space. SkinCeuticals’ Next-generation C E Ferulic Serum SkinCeuticals is rolling out the next generation of C E Ferulic.
Open in Who Shared Issue with article?

K-Beauty Comes to the US: Hugel’s Wellage Debuts at Olive Young

|
By Denise Mann Verified
| The Dermatology Digest
Hugel is expanding its US presence through retail. Its clinical skincare brand Wellage is now available in Olive Young’s first US brick-and-mortar store in Pasadena, CA. The lineup consists of six products from the Real Hyaluronic Blue 100 Ampoule, two from the Cica Calming line, and one product from the PDRN line. The US Food and Drug Administration (FDA) approved Hugel’s letibotulinumtoxinA-wlb (Letybo) for moderate-to-severe glabellar lines in adults in 2024.
Open in Who Shared Issue with article?

From Lab to Pharmacy: The Journey to FDA Approval for a Multiple Myeloma Drug

|
By Neha Pathak Verified, Denise Mann Verified
| WebMD Verified
The results are remarkable. The combination is now an attractive second-line therapy for patients with relapsed myeloma. Hearn Jay Cho, MD, PhD A new drug's journey from bench to bedside can take decades, and the path is often riddled with detours. The discovery process starts with an idea, an insight, or even just keen interest.
Open in Who Shared Issue with article?
See all 30,086 licensed articles (30,812 Total)